Immune responses against helicobacter pylori in gastric cancer patients and in risk groups for gastric cancer

Helicobacter

Volumn 18, Issue 1, 2013, Pages 73-82

  Adamsson, Jenni ^a   Lundin, Samuel B ^a   Hansson, Lars Erik ^a   Sjövall, Henrik ^a   Svennerholm, Ann Mari ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Antibody profile; Gastric cancer; H. pylori

Indexed keywords

CAGA PROTEIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MEMBRANE PROTEIN; PEPSINOGEN I; PEPSINOGEN II; UREASE;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; ATROPHIC GASTRITIS; BACTERIUM CULTURE; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; DUODENUM ULCER; FEMALE; HELICOBACTER INFECTION; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROLOGY; SERUM; SEX DIFFERENCE; STOMACH BIOPSY; STOMACH CANCER; STOMACH ULCER;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; FEMALE; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; SERUM; STOMACH NEOPLASMS;

HELICOBACTER PYLORI;

EID: 84872406007     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2012.00991.x     Document Type: Article

References (31)

1. McColl KE, el-Omar E. Helicobacter pylori and disturbance of gastric function associated with duodenal ulcer disease and gastric cancer. Scand J Gastroenterol Suppl 1996;215:32-7.
2. El-Omar EM, Oien K, El-Nujumi A, Gillen D, Wirz A, Dahill S, Williams C, Ardill JE, McColl KE. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997;113:15-24.
3. Hansson LE, Nyren O, Hsing AW, Bergstrom R, Josefsson S, Chow WH, Fraumeni JF Jr, Adami HO. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 1996;335:242-9.
4. Kreuning J, Lindeman J, Biemond I, Lamers CB. Relation between IgG and IgA antibody titres against Helicobacter pylori in serum and severity of gastritis in asymptomatic subjects. J Clin Pathol 1994;47:227-31.
5. Rautelin HI, Oksanen AM, Karttunen RA, Seppala KM, Virtamo JR, Aromaa AJ, Kosunen TU. Association of CagA-positive infection with Helicobacter pylori antibodies of IgA class. Ann Med 2000;32:652-6.
6. Yamaji Y, Mitsushima T, Ikuma H, Okamoto M, Yoshida H, Kawabe T, Shiratori Y, Saito K, Yokouchi K, Omata M. Weak response of Helicobacter pylori antibody is high risk for gastric cancer: a cross-sectional study of 10, 234 endoscoped Japanese. Scand J Gastroenterol 2002;37:148-53.
7. Aromaa A, Kosunen TU, Knekt P, Maatela J, Teppo L, Heinonen OP, Harkonen M, Hakama MK. Circulating anti-Helicobacter pylori immunoglobulin A antibodies and low serum pepsinogen I level are associated with increased risk of gastric cancer. Am J Epidemiol 1996;144:142-9.
8. Manojlovic N, Babic D, Filipovic-Ljeshovic I, Pilcevic D. Anti Helicobacter pylori IgG and IgA response in patients with gastric cancer and chronic gastritis. Hepatogastroenterology 2008;55:807-13.
9. Tulinius H, Ogmundsdottir HM, Kristinsson KG, Sigvaldason H, Sigvaldadottir E, Kristjansdottir G, Sigfusson N. Helicobacter pylori antibodies and gastric cancer in Iceland - The decline in IgG antibody level is a risk factor. APMIS 2001;109:835-41.
10. Quiding-Jarbrink M, Sundstrom P, Lundgren A, Hansson M, Backstrom M, Johansson C, Enarsson K, Hermansson M, Johnsson E, Svennerholm AM. Decreased IgA antibody production in the stomach of gastric adenocarcinoma patients. Clin Immunol 2009;131:463-71.
11. Mattsson A, Tinnert A, Hamlet A, Lonroth H, Bolin I, Svennerholm AM. Specific antibodies in sera and gastric aspirates of symptomatic and asymptomatic Helicobacter pylori-infected subjects. Clin Diagn Lab Immunol 1998;5:288-93.
12. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81.
13. Mukoubayashi C, Yanaoka K, Ohata H, Arii K, Tamai H, Oka M, Ichinose M. Serum pepsinogen and gastric cancer screening. Intern Med 2007;46:261-6.
14. Miki K, Ichinose M, Kawamura N, et al. The significance of low serum pepsinogen levels to detect stomach cancer associated with extensive chronic gastritis in Japanese subjects. Jpn J Cancer Res 1989;80:111-4.
15. Lindgren A, Yun CH, Sjoling A, Berggren C, Sun JB, Jonsson E, Holmgren J, Svennerholm AM, Lundin SB. Impaired IFN-gamma production after stimulation with bacterial components by natural killer cells from gastric cancer patients. Exp Cell Res 2011;317:849-58.
16. Lundin BS, Enarsson K, Kindlund B, Lundgren A, Johnsson E, Quiding-Jarbrink M, Svennerholm AM. The local and systemic T-cell response to Helicobacter pylori in gastric cancer patients is characterised by production of interleukin-10. Clin Immunol 2007;125:205-13.
17. Cover TL, Glupczynski Y, Lage AP, Burette A, Tummuru MK, Perez-Perez GI, Blaser MJ. Serologic detection of infection with cagA+ Helicobacter pylori strains. J Clin Microbiol 1995;33:1496-500.
18. Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997;40:297-301.
19. Graham DY, Rakel RE, Fendrick AM, Go MF, Marshall BJ, Peura DA, Scherger JE. Recognizing peptic ulcer disease. Keys to clinical and laboratory diagnosis. Postgrad Med 1999;105:113-6, 21-3, 27-8 passim.
20. Suzuki G, Cullings H, Fujiwara S, Hattori N, Matsuura S, Hakoda M, Akahoshi M, Kodama K, Tahara E. Low-positive antibody titer against Helicobacter pylori cytotoxinassociated gene A (CagA) may predict future gastric cancer better than simple seropositivity against H. pylori CagA or against H. pylori. Cancer Epidemiol Biomarkers Prev 2007;16:1224-8.
21. Schmausser B, Eck M, Greiner A, Luhrs H, Vollmers HP, Muller-Hermelink HK. Disparity between mucosal and serum IgA and IgG in Helicobacter pylori infection. Virchows Arch 2002;441:143-7.
22. Crabtree JE, Wyatt JI, Sobala GM, Miller G, Tompkins DS, Primrose JN, Morgan AG. Systemic and mucosal humoral responses to Helicobacter pylori in gastric cancer. Gut 1993;34:1339-43.
23. Matsukura N, Onda M, Tokunaga A, Matsuda N, Yamashita K. Mucosal IgA antibody against Helicobacter pylori in chronic gastritis and intestinal metaplasia detected by the Tes-Tape method in resection specimens after gastrectomy for gastric cancer. Cancer 1995;75(6 Suppl):1472-7.
24. Stemmermann GN, Samloff IM, Nomura A, Walsh JH. Serum pepsinogen I and gastrin in relation to extent and location of intestinal metaplasia in the surgically resected stomach. Dig Dis Sci 1980;25:680-7.
25. Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, Barbosa J, Guilherme M, Moreira-Dias L, Lomba-Viana H, Silva R, Abreu N, Lomba-Viana R. Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma. Neoplasia 2004;6:449-56.
26. Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis 2007;8:8-14.
27. Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 1999;44:693-7.
28. Adachi Y, Yasuda K, Inomata M, Sato K, Shiraishi N, Kitano S. Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. Cancer 2000;89:1418-24.
29. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31-49.
30. Ming SC. Gastric carcinoma. A pathobiological classification. Cancer 1977;39:2475-85.
31. Noda S, Soejima K, Inokuchi K. Clinicopathological analysis of the intestinal type and diffuse type of gastric carcinoma. Jpn J Surg 1980;10:277-83.